Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients


Por: Molica, M, Miralles, G, Dillon, R, Annunziata, M, Basheer, F, Bergua, JM, Calmet, FV, Campbell, V, Cetin, D, Cimino, G, Ciotti, G, Corbingi, A, De Fazio, L, Erol, HA, Federico, V, Gil, C, Gulu, YM, Malcorra, AB, Mariani, S, Mazzone, C, Mulè, A, Musuraca, G, Khan, A, Norata, M, O'Nions, J, Palumbo, FE, Papayannidis, C, Piccioni, AL, Rubio, MTO, Sanchez-Tovar, J, Serin, I, Serrao, A, Sevindik, OG, Sucato, G, Urbano, MA, Vetro, C, Vives, S, Rossi, M, Martelli, MP, Montesinos, P, Othman, J and Perrone, S

Publicada: 1 ene 2026 Ahead of Print: 1 nov 2025
Resumen:
Gilteritinib is a selective FLT3 inhibitor approved for the treatment of relapsed or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) following >= 1 prior line of therapy. However, data on its effectiveness in later-line settings is limited. We conducted a multicenter, retrospective study including 171 adult patients with R/R FLT3-mutated AML who received gilteritinib as third-line or beyond between August 2017 and March 2024 across centers in Italy, Spain, the United Kingdom, and Turkey. The primary endpoint was overall survival (OS). Secondary endpoints included overall response rate (ORR), composite complete remission (cCR), duration of response. Among the 171 patients, 84% carried FLT3-ITD mutations and 26% had received >= 3 prior lines of therapy. The cCR rate was 28%, and ORR was 47%. Patients who were younger and presented with relapsed (vs. refractory) disease had better outcomes. Prior exposure to venetoclax or allogeneic hematopoietic stem cell transplantation (HSCT) was associated with inferior response. Gilteritinib enabled HSCT in 12% of patients. Median OS was 7.1 months (95% CI, 5.9-10.1), and in Cox-regression analysis was significantly improved among responders and those who underwent HSCT (median OS: 21.5 months; 95% CI, 12.8-NR). Prior venetoclax exposure was associated with shorter survival (5.7 months; 95% CI, 5.1-8.8). On multivariate analysis, previous exposure to venetoclax and FLT3 inhibitors was the strongest predictor of reduced response rates. Despite heavy pretreatment, gilteritinib retained clinically relevant activity in later-line R/R FLT3-mutated AML. Its use beyond second-line may serve as a bridge to HSCT in selected patients. Resistance mechanisms, particularly following venetoclax, remain a therapeutic challenge. These data support the continued use of gilteritinib beyond second-line and highlight the need for prospective studies to optimize sequencing strategies.

Filiaciones:
Molica, M:
 Azienda Univ Osped Renato Dulbecco, Dept Hematol Oncol, Catanzaro, Italy

Miralles, G:
 Hosp Gen Elche, Alicante, Spain

Dillon, R:
 Kings Coll London, Dept Med & Mol Genet, London, England

Annunziata, M:
 Cardarelli Hosp, Hematol Unit, Naples, Italy

Basheer, F:
 Addenbrookes Hosp, Dept Haematol, Cambridge, England

Bergua, JM:
 Hosp San Pedro Alcantara, Dept Hematol, Caceres, Spain

Calmet, FV:
 Hosp Univ Mutua Terrassa, Hematol Dept, Terrassa, Spain

Campbell, V:
 Western Gen Hosp, Edinburgh, Scotland

Cetin, D:
 Ege Univ, Sch Med, Dept Hematol, Izmir, Turkiye

Cimino, G:
 Univ Perugia, Dept Med & Surg, Hematol, CREO, Perugia, Italy

 Azienda Osped Perugia, Perugia, Italy

Ciotti, G:
 Ist Oncol Veneto IOV IRCCS, UOC Oncohematol, Dept Oncol, Padua, Italy

Corbingi, A:
 Polo Univ Pontino, S M Goretti Hosp, Dept Hematol, Latina, Italy

De Fazio, L:
 Azienda Univ Osped Renato Dulbecco, Dept Hematol Oncol, Catanzaro, Italy

Erol, HA:
 Kocaeli Univ, Fac Med, Dept Hematol, Kocaeli, Turkiye

Federico, V:
 Vito Fazzi Hosp, Hematol & Transplant Unit, Lecce, Italy

Gil, C:
 Hosp Gen Alicante, Alicante, Spain

Gulu, YM:
 Gaziantep City Hosp, Dept Hematol, Gaziantep, Turkiye

Malcorra, AB:
 Hosp Univ Cruces, San Vicente De Barakaldo, Bizkaia, Spain

Mariani, S:
 Sapienza Univ Rome, Univ Hosp St Andrea, Dept Hematol, Rome, Italy

Mazzone, C:
 St Eugenio Hosp, Hematol Unit, Rome, Italy

Mulè, A:
 AOOR Villa Sofia Cervello, Hematol Unit, Palermo, Italy

Khan, A:
 Leeds Teaching Hosp Trust, Dept Haematol, Leeds, England

O'Nions, J:
 Univ Coll London Hosp NHS Fdn Trust, London, England

Palumbo, FE:
 AOU Policlin G RodolicoSan Marco, Div Hematol, Catania, Italy

Papayannidis, C:
 IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

Piccioni, AL:
 San Giovanni Addolorata Hosp, Dept Hematol, Rome, Italy

Rubio, MTO:
 Hosp Clin Univ Lorenzo Blesa, Zaragoza, Spain

Sanchez-Tovar, J:
 Hosp Rio Carrion, Complejo Asistencial Palencia, Palencia, Spain

Serin, I:
 Istanbul Basaksehir Cam & Sakura City Hosp, Dept Hematol, Istanbul, Turkiye

Serrao, A:
 San Camillo Hosp, Hematol Unit, Rome, Italy

Sevindik, OG:
 Istanbul Florence Nightingale Hosp, Clin Hematol, Istanbul, Turkiye

Sucato, G:
 Univ Hosp Paolo Giaccone, Hematol Unit, Palermo, Italy

Urbano, MA:
 A Perrino Hosp, Hematol Unit, Brindisi, Italy

Vetro, C:
 Paracelsus Med Univ PMU, Hosp Bolzano SABES ASDAA, Teaching Hosp, Hematol & Bone Marrow Transplantat Unit BMTU, Bolzano, Italy

:
 Hosp U Germans Trias i Pujol ICO, Badalona, Spain

Rossi, M:
 Azienda Univ Osped Renato Dulbecco, Dept Hematol Oncol, Catanzaro, Italy

Martelli, MP:
 Univ Perugia, Dept Med & Surg, Hematol, CREO, Perugia, Italy

 Azienda Osped Perugia, Perugia, Italy

Montesinos, P:
 La Fe Univ & Polytech Hosp, Hematol Dept, Valencia, Spain

Othman, J:
 Kings Coll London, Dept Med & Mol Genet, London, England

Perrone, S:
 Polo Univ Pontino, S M Goretti Hosp, Dept Hematol, Latina, Italy
ISSN: 03618609





American Journal of Hematology
Editorial
John Wiley & Sons Inc., 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Estados Unidos America
Tipo de documento: Article
Volumen: 101 Número: 1
Páginas: 89-96
WOS Id: 001620148800001
ID de PubMed: 41273181
imagen hybrid

MÉTRICAS